Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Chlorhexidine gluconate, Isopropyl alcohol may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for
ChloraPrep is a cutaneous solution of chlorhexidine gluconate and isopropyl alcohol, which is presented as a plastic stick with a foam pad that is impregnated with a fast-acting antiseptic solution on one end. The product is used to disinfect the skin and help prevent infections before invasive medical procedures. 2.
e ChloraPrep
Do not use ChloraPrep: if you are allergic (hypersensitive) to chlorhexidine gluconate or any of the other ingredients of ChloraPrep, especially if you have a history of possible chlorhexidine-related allergic reactions (listed in section 6). in the ear canal, as the solution may damage your hearing. Warnings and precautions Talk to your doctor, pharmacist or nurse before using ChloraPrep. ChloraPrep is for external use only. ChloraPrep should not be used: near delicate linings (mucous membranes), as it may cause irritation. If it does get onto the delicate linings of the body passages, it should be washed quickly with plenty of water. on open skin wounds and broken or damaged skin. in direct contact with neural tissue (for example brain and spinal cord tissue). ChloraPrep must not come into contact with the eye due to the risk of visual damage. If it comes into contact with the eyes, wash out immediately and thoroughly with water. In case of any irritation, redness or pain in the eye, or visual disturbance, ask for medical advice promptly. Serious cases of persistent corneal injury (injury to the surface of the eye) potentially requiring corneal 2
transplant have been reported when similar products have accidentally come in contact with the eye during surgical procedures, in patients under general anaesthesia (deep painless sleep). ChloraPrep may in rare cases cause severe allergic reactions, leading to a drop in blood pressure and even to unconsciousness. Early symptoms of a severe allergic reaction may be skin rash or asthma. If you notice these symptoms, stop using ChloraPrep and contact your doctor as soon as possible (see under section 4: "Possible side effects"). ChloraPrep should only be applied to the skin gently. When the solution is applied in an over- vigorous manner to very fragile or sensitive skin or after repeated use, rash, inflammation, itching, dry and/or flaky skin and pain may occur. At the first sign of any of these reactions, applications of ChloraPrep should be stopped. Prolonged skin contact should be avoided. Soaked materials, such as drapes or gowns should be removed before use. The solution should not be allowed to pool. The solution is flammable. Do not use ignition sources, naked flames or strong heat sources near the treated areae until the skin is completely dry. Children Use with care in newborn babies, especially those born prematurely. ChloraPrep may cause chemical skin burns. Other medicines and ChloraPrep Tell your doctor, pharmacist or nurse if you have recently had a vaccine or skin test injection (patch test used to test for allergies). Pregnancy, breast-feeding and fertility There are no studies with ChloraPrep in pregnant or lactating women. Pregnancy No effects during pregnancy are anticipated, since systemic exposure to chlorhexidine gluconate is negligible. ChloraPrep can be used during pregnancy. Breast-feeding No effects on the breastfed newborn/infant are anticipated since the systemic exposure of the breast-feeding woman to chlorhexidine gluconate is negligible. ChloraPrep can be used during breast- feeding. Fertility The effects of chlorhexidine gluconate on human reproduction have not been studied. Driving and using machines ChloraPrep does not affect your driving or ability to use machines. 3.
ChloraPrep
The antiseptic solution is kept inside an aluminium pouch that also contains the swab(s). Your doctor, pharmacist or nurse will select the pouch size and the number of ChloraPrep swabs needed, based on the procedure site and area of skin to be covered. Your doctor, pharmacist or nurse will rub the foam pad gently over your skin, covering the skin area that needs to be prepared. Depending on your medical procedure, more than one pouch may be used. Other ChloraPrep applicators may be more suitable, depending on the medical procedure being undertaken. ChloraPrep is only used on the intact skin and each swab is only used once. 3
If you have any further questions on the use of this product, ask your doctor, pharmacist or nurse. 4.
Like all medicines, this medecine can cause side effects, although not everybody gets them. If you experience any of the following reactions the product application should be stopped: swelling of the face, lips, tongue or throat; a red itchy skin rash; wheezing or difficulty breathing; feeling faint and dizzy; a strange metallic taste in the mouth; collapse. You may be having an allergic reaction. If you develop a rash or your skin becomes itchy, painful, red, blistery, dry or inflamed where you have used the product, stop using ChloraPrep and talk to your doctor, pharmacist or nurse. Very rarely (fewer than 1 in 10,000 people), allergic or irritated skin reactions to the ingredients in ChloraPrep (chlorhexidine gluconate and isopropyl alcohol) have been reported. Other possible side effects, for which it is not known how often they occur, are: eye irritation, pain, chemical burns, corneal injury (injury to the surface of the eye), and permanent eye damage including permanent visual impairment (following accidental ocular exposure during head, face and neck surgical procedures) in patients under general anaesthesia (deep painless sleep) and skin burns in newborns/infants. Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via Yellow Card Scheme, Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine. 5.
ChloraPrep
Keep this medicine out of the sight and reach of children. This medicine does not require any special temperature storage conditions. Store in the original package; ChloraPrep is sterile unless the seal is broken. Flammable. Avoid exposure of the container and contents to naked flames during use, storage or disposal. Do not use this medicine after the expiry date which is stated on the label or carton after EXP. The expiry date refers to the last day of that month. Do not throw away medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment. 6.
What ChloraPrep contains –
–
The active substances are chlorhexidine gluconate and isopropyl alcohol. Each single swab pouch of 1.75 mL solution contains 35 mg of chlorhexidine gluconate (20 mg/mL) and 1.23 mL of isopropyl alcohol (0.70 mL/mL). Each three-swab pouch of 5.25 mL solution contains 105 mg of chlorhexidine gluconate (20 mg/mL) and 3.7 mL of isopropyl alcohol (0.70 mL/mL). The other ingredient is purified water. 4
What ChloraPrep looks like and contents of the pack ChloraPrep swabs consist of a plastic stick connected to an impregnated foam tip, which are sealed in a plastic foil pouch containing the antiseptic solution. A pouch can contain either one or three swabs. Pack Sizes: 1.75 mL (Single swab): 5.25 mL (Triple swab):
Carton of 48 pouches (total: 48 swabs) Carton of 40 pouches each containing 3 swabs (total: 120 swabs)
Not all pack sizes may be marketed Marketing Authorisation Holder and Manufacturer The Marketing Authorisation holder of ChloraPrep is: Becton Dickinson UK Ltd 1030 Eskdale Road, Winnersh, Wokingham RG41 5TS, United Kingdom Customer contact for adverse events or medical information inquiries: +44 800 043 7546 The Manufacturer of ChloraPrep is Insight Health Limited Unit A Bridgefields, Welwyn Garden City, Hertfordshire AL7 1RX United Kingdom This medicine is authorised in the Member States of the European Economic Area and in the United Kingdom and in the United Kingdom under the following names: Finland: ChloraPrep 20 mg/ml + 0,70 ml/ml kyllästetty lääketuppo iholle France: CHLORAPREP, tampon cutané imprégné en applicateur Germany: ChloraPrep 2 % w/v / 70 % v/v Imprägnierter Tupfer zur Anwendung auf der Haut Ireland: ChloraPrep 2% w/v / 70% v/v impregnated cutaneous swab Italy: ChloraPrep 2% p/v / 70% v/v tampone cutaneo medicato Norway: Chloraprep 20 mg/ml + 0,70 ml/ml impregnert vattpinne til bruk på hud Sweden: Chloraprep 20 mg/ml + 0,70 ml/ml impregnerad kutan svabb United Kingdom: ChloraPrep 2% w/v / 70% v/v impregnated cutaneous swab This leaflet was last revised in 01/2026. Licence Number: PL 05920/0006 —————————————————————————————————————————-The following information is intended for healthcare professionals only: ChloraPrep 2% w/v / 70% v/v impregnated cutaneous swab chlorhexidine gluconate / isopropyl alcohol Instructions for using ChloraPrep: 5
For cutaneous use. For external use only. Choose the appropriate ChloraPrep presentation based on the invasive procedure being undertaken and the size of the area to be prepared in order to avoid administering excess solution and the risk of product pooling. Other ChloraPrep applicators may be more suitable depending on the medical procedure being undertaken. –
Only the inside of the pouch is sterile. In order to preserve sterility, the pouch should be opened carefully, and the foam pad should not be allowed to touch any non-sterile surface. Tear the pouch at its side notch to reveal the swab handle(s). Do not touch the swab foam pad. Place the foam pad flat-side down on the treatment area of the patient's skin. Apply the solution for 30 seconds using a gentle back and forth motion. Allow the covered area to air dry completely. For triple swabs, use the swabs sequentially for a total of 30 seconds.
ChloraPrep solution can be left on the skin post procedure. Maximum coverage areas:
6 cm x 7 cm 10 cm x 16 cm
Precautions for Use:
Do not use excessive quantities of ChloraPrep and do not allow the solution to pool in skin folds or under the patient or drip on sheets or other material in direct contact with the patient.
–
Use with care in neonates, especially those born before 32 weeks of gestation and within the first 2 weeks of life. ChloraPrep may cause chemical skin burns.
–
Do not use near mucous membranes, as it may cause irritation, pain and chemical burns. If it does get into the mucous membranes, it should be washed quickly with plenty of water.
–
ChloraPrep must not come into contact with the eye due to the risk of visual damage. If it comes into contact with the eyes, wash out immediately and thoroughly with water. An ophthalmologist's advice should be sought.
–
Do not use on open skin wounds, broken or damaged skin.
–
ChloraPrep should not come into contact with neural tissues. To prevent exposure of the middle ear to ChlorPrep via a perforation of the eardrum, the use of ChloraPrep in the ear canal is contraindicated.
–
Chlorhexidine is incompatible with soap and other anionic agents.
–
Alcohol should not be brought into contact with some vaccines and skin test injections (patch tests). If in doubt, consult the vaccine manufacturer's literature.
–
Do not apply the solution in an over vigorous manner to very fragile or sensitive skin. After repeated use, local skin reaction may occur including erythema or inflammation, itching, dry and/or flaky skin and local application site pain. At the first sign of local skin reaction, stop application of ChloraPrep.
–
Do not use in patients with known hypersensitivity to the active substances or to any of the excipients, especially in those with a history of possible chlorhexidine-related allergic reactions.
–
Chlorhexidine-containing products are known causes of anaphylactic reactions during anaesthesia. If symptoms of an anaphylactic reaction are detected during anaesthesia (e.g. abrupt fall in blood pressure, hives, angioedema), chlorhexidine-related allergic reaction should be considered.
–
Special precaution should be taken to avoid patient exposure to any other product containing chlorhexidine during the course of the treatment.
6
Special precautions for disposal The product is for single use. The solution is flammable. Avoid exposure of the container and contents to naked flames during use, storage or disposal. Discard the swab after use as per clinical waste procedures. Please refer to the Summary of Product Characteristics of ChloraPrep for further detailed information. Storage Procedures ChloraPrep is for single use only and is sterile until the packaging is opened. Do not use ChloraPrep after the expiry date stated on the label or carton. The expiry date refers to the last day of that month. This medicine does not require any special temperature storage conditions. Store in the original package. Active Substances The active substances in ChloraPrep are 2% w/v chlorhexidine gluconate and 70% v/v isopropyl alcohol. The inactive ingredient in ChloraPrep is purified water. Marketing Authorisation Holder Becton Dickinson UK Ltd 1030 Eskdale Road, Winnersh, Wokingham, RG41 5TS, United Kingdom
7
The active substance in ChloraPrep Swabstick is chlorhexidine gluconate, isopropyl alcohol.
Medicines with the same active substance, strength and form include: ChloraPrep Clear, ChloraPrep with Tint. They are interchangeable only if your prescriber or pharmacist says so.
This leaflet reproduces the patient information leaflet approved for ChloraPrep Swabstick, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
The medicinal product is to be used for disinfection of the skin prior to invasive medical procedures.
Posology
ChloraPrep may be used in all age groups and patient populations (see section on paediatric population, below).
Paediatric population
ChloraPrep should be used with care in newborn babies, especially those born prematurely (see also section 4.4, Special warnings and precautions for use).
Method of administration
For cutaneous use.
One pouch contains either one swab (1.75 mL) or three swabs (5.25 mL).
The choice of pouch will depend on the invasive procedure being undertaken and the clinician's preference.
Applicator
Maximum Coverage Area (cm x cm)
For Procedures such as:
1.75 mL (Single swab)
6 x 7
- Routine venipuncture
- Blood culture collection
- Peripheral (arterial line) cannulation
- Simple biopsy
5.25 mL (Triple swabs)
10 x 16
- Midline & Central Venous Catheter (CVC) insertion and maintenance
- Peritoneal dialysis site cleansing
• Only the inside of the pouch is sterile. In order to preserve sterility, the pouch should be opened carefully and the foam pad should not be allowed to touch any non-sterile surface.
• Tear the pouch at its side notch to reveal the swab handle(s). Do not touch the swab foam pad.
• Place the foam pad flat-side down on the treatment area of the patient's skin.
• Apply the solution for 30 seconds using a gentle back and forth motion.
• The area covered should be allowed to air dry completely.
• For triple swabs, use the swabs sequentially for a total of 30 seconds.
Choose the appropriate ChloraPrep presentation based on the invasive procedure being undertaken and the size of the area to be prepared in order to avoid administering excess solution and the risk of product pooling (see section 4.4).
Other ChloraPrep applicators may be more suitable depending on the medical procedure being undertaken.
It is recommended that ChloraPrep solution remains on the skin post-procedure to provide continued antimicrobial activity. If removal is necessary, remove with soap and water or alcohol.
Hypersensitivity to the active substances or to any of the excipients listed in section 6.1, especially in those with a history of possible chlorhexidine-related allergic reactions (see sections 4.4 and 4.8).
Use in the ear canal due to the risk of ototoxicity (see section 4.4).
The solution is flammable. Do not use electrocautery procedures or other ignition sources until the skin is completely dry.
Remove any soaked materials, drapes, or gowns before proceeding with the intervention. Do not use excessive quantities of ChloraPrep and do not allow the solution to pool in skin folds or under the patient, or drip on sheets or other material in direct contact with the patient. Where occlusive dressings are to be applied to areas previously exposed to ChloraPrep, care must be taken to ensure no excess product is present prior to application of the dressing.
For external use only on intact skin.
ChloraPrep contains chlorhexidine. Chlorhexidine is known to induce hypersensitivity, including generalised allergic reactions and anaphylactic shock. The prevalence of chlorhexidine hypersensitivity is not known, but available literature suggests this is likely to be very rare. ChloraPrep should not be administered to anyone with a potential history of an allergic reaction to a chlorhexidine-containing compound (see sections 4.3 and 4.8). The solution is an irritant to mucous membranes. It should therefore be kept away from these areas.
ChloraPrep must not come into contact with the eye. Serious cases of persistent corneal injury, potentially requiring corneal transplant, were reported following accidental ocular exposure to chlorhexidine containing medicinal products despite taking eye protective measures due to migration of solution beyond the intended surgical preparation area. Extreme care must be taken during application to ensure that ChloraPrep does not migrate beyond its intended application site into the eyes. Particular care should be taken in anaesthetised patients, who are unable to immediately report ocular exposure. If ChloraPrep comes into contact with the eyes, wash out promptly and thoroughly with water. An ophthalmologist's advice should be sought.
Do not use on open skin wounds. Do not use on broken or damaged skin. In addition, direct contact with neural tissue must be avoided. When the middle ear is exposed to chlorhexidine there is a risk of ototoxicity. To prevent exposure of the middle ear to ChlorPrep via a perforation of the eardrum, the use of ChloraPrep in the ear canal is contraindicated (see section 4.3).
It is important to ensure that the correct method of application is strictly followed (see section 4.2 above).
Prolonged skin contact with alcohol containing solutions should be avoided.
When the solution has been applied in an over-vigorous manner to very fragile or sensitive skin or after repeated use, local skin reaction may occur including: erythema or inflammation, itching, dry and/or flaky skin and local application site pain. At the first sign of local skin reaction, application of ChloraPrep should be stopped.
Anaphylactic reactions during anaesthesia
Chlorhexidine-containing products are known causes of anaphylactic reactions during anaesthesia.
The symptoms of anaphylactic reactions might be masked in an anesthetised patient e.g. a significant portion of skin may be covered or patient unable to communicate early symptoms. If symptoms of an anaphylactic reaction are detected during anaesthesia (e.g. abrupt fall in blood pressure, hives, angioedema), chlorhexidine-related allergic reaction should be considered.
When chlorhexidine-related allergic reaction during anaesthesia is suspected, other products containing chlorhexidine used during anaesthesia (e.g. IV lines) should be removed. Special precaution should be taken to avoid patient exposure to any other product containing chlorhexidine during the course of the treatment.
Paediatric population
The use of chlorhexidine solutions, both alcohol-based and aqueous, for skin antisepsis prior to invasive procedures has been associated with chemical burns in neonates. Based on available case reports and the published literature, this risk appears to be higher in preterm infants, especially those born before 32 weeks of gestation and within the first 2 weeks of life.
Alcohol should not be brought into contact with some vaccines and skin test injections (patch tests). If in doubt, consult the vaccine manufacturer's literature.
There are no studies with this product in pregnant or lactating women.
Pregnancy
No effects during pregnancy are anticipated since systemic exposure to chlorhexidine gluconate is negligible. ChloraPrep can be used during pregnancy.
Breast-feeding
No effects on the breastfed newborn/infant are anticipated since the systemic exposure of the breast-feeding woman to chlorhexidine gluconate is negligible. ChloraPrep can be used during breast-feeding.
Fertility
The effects of chlorhexidine gluconate on human reproduction have not been studied.
ChloraPrep has no or negligible influence on the ability to drive and use machines.
Skin and subcutaneous tissue disorders:
Very rarely (<1/10,000) allergic or irritation skin reactions have been reported with chlorhexidine and isopropyl alcohol including: erythema, rash (e.g. erythematous, papular, or maculopapular), pruritus and blisters or application site vesicles. Other local symptoms have included skin burning sensation, pain and inflammation.
Frequency not known (cannot be estimated from the available data): dermatitis, eczema, urticaria, chemical burns in neonates.
Immune system disorders:
Frequency not known (cannot be estimated from the available data): Hypersensitivity including anaphylactic shock (see sections 4.3 and 4.4).
The most commonly reported adverse reactions are associated with application site reactions. These were noted to occur most often within the area of application of the solution (i.e. at the skin preparation site) and very rarely spread. The adverse reactions were often self-limiting in nature or resolved following treatment with topical steroids and / or antihistamines. The most commonly reported reactions were non-serious in nature and included application site rash, application site erythema, application site vesicles, application site pain and application site pruritus. Frequency, type and severity of adverse reactions in children are expected to be the same as in adults.
Cases of anaphylactic reactions have been reported during anaesthesia.
Eye disorders:
Frequency not known (cannot be estimated from the available data): Eye irritation, pain, hyperaemia, corneal erosion, epithelium defect/corneal injury, significant permanent visual impairment*.
*Cases of severe corneal erosion and permanent significant visual impairment due to inadvertent ocular exposure have been reported post-marketing, leading to some patients requiring corneal transplant (see section 4.4).
Description of selected adverse reactions
There have been isolated spontaneous reports of generalised allergic reactions potentially associated with ChloraPrep solution that have been reported during anaesthesia. In some cases, the patient may have had a pre-existing sensitivity to chlorhexidine (see Section 4.4).
This product may cause a severe allergic reaction. Symptoms may include wheezing/difficulty breathing, shock, facial swelling, hives, or rash. Use of ChloraPrep is contra-indicated where patients have shown previous hypersensitivity to chlorhexidine or isopropyl alcohol (see Section 4.3).
In case of hypersensitivity or allergic reaction, stop the product application immediately.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme
Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
There are no reports of overdose with this product.
Ask anything about ChloraPrep Swabstick. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.